

Our COVID-19 solutions key facts...

We are working with scientific partners to develop a broad portfolio of potential COVID-19 solutions

9 June 2021 Update 13

...our science and technology

We are using our adjuvant technology to develop several protein-based adjuvanted COVID-19 vaccines, partnering with Sanofi, SK Bioscience of South Korea and Medicago of Canada. Our collaboration with Medicago is now in late-stage trials

What is an adjuvant? An adjuvant can be added to a vaccine to boost the body's immune response, which means less vaccine is needed for the same result. This is particularly important in a pandemic as more vaccine doses can be available to protect people around the world

We are also investigating next generation COVID-19 vaccines, expanding our work with CureVac of Germany, who are amongst a small number of companies pioneering mRNA technology, to jointly develop next-generation mRNA COVID-19 vaccines which could address multiple variants in a single vaccine. We are also supporting the manufacture of up to 100 million doses of CureVac's first generation COVID-19 vaccine in 2021 have reached an agreement with Novavax and the UK Government Vaccines Taskforce to support manufacturing of up to 60 million doses of Novavax's COVID-19 vaccine candidate and are in discussions with a number of other companies to explore whether we can help manufacture their COVID-19 vaccines

In addition to vaccines, we are developing potential treatments for COVID-19, including collaborating with Vir Biotechnology to develop new dual action monoclonal antibodies, which could be used as therapeutic or preventive options to fight this and future outbreaks. Following interim analysis of clinical data from our lead antibody candidate – investigating it in adults at high risk of hospitalisation – the European Medicines Agency's (EMA) Committee for Human Medicinal Products has issued a positive scientific opinion. The EMA's recommendations can now be used to support national advice on the possible use of this monoclonal antibody before a marketing authorisation is issued.

In addition, we received Emergency Use Authorisation from the U.S. Food and Drug Administration for the same monoclonal antibody for the treatment of mild-to-moderate COVID-19 in high risk adults and paediatric patients. A second antibody from our collaboration with Vir Biotechnology is also being investigated as a potential COVID-19 treatment

We are also conducting a trial to assess whether a GSK monoclonal antibody already in development can help treat hospitalised patients aged 70 and over who are affected by COVID-19 related pulmonary disease. Results are expected later in 2021

Across all of our COVID-19 solutions, we are committed to: working in partnership; taking a global approach; ensuring a commitment to access; and supporting future pandemic preparedness

...our existing products

We are ensuring continuous supply of our medicines, vaccines and consumer healthcare products with 20,000 employees working in our R&D and manufacturing sites around the world

We have also donated over 1.4 million products across 27 countries

...our capabilities and expert facilities

We have set up specialised laboratory space to help support national diagnostic testing in the UK and Belgium

In addition, we are providing free curriculum STEM resources online in the UK and US, supporting teachers and students with in school and remote learning

...supporting frontline health workers

We have made a \$10 million donation to WHO and the UN Foundation's COVID-19 Solidarity Response Fund to prevent, detect, and manage the pandemic in support of frontline health workers

We have donated lab equipment, instruments, and scientific kits to support government testing and **over 800,000 PPE units** to protect frontline health workers in 34 countries



COVID-19 virus